ANGO · Angiodynamics Inc · Executive Compensation

$15.54 +0.43 (+2.85%)

Russell 2000 member Rebalance outlook locked

Market Cap

$627.84M

42.05M

Volume · Oct 5 636.19K Avg daily vol (3M) 496.13K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
James C. Clemmer	President, CEO	$803,027	—	$2,628,871	$808,207	$1,215,608	$38,572	$5,494,285
James Clemmer	CEO	$803,027	—	$2,628,871	$808,207	$1,215,608	$38,572	$5,494,285
Stephen Trowbridge	EVP, CFO Lawrence T. Weiss SVP & Chief Legal Officer	$455,847	—	$934,085	$287,497	$449,664	$34,704	$2,161,797
Stephen A. Trowbridge	EVP, CFO Lawrence T. Weiss SVP & Chief Legal Officer	$455,847	—	$934,085	$287,497	$449,664	$34,704	$2,161,797
Laura Piccinini	SVP & GM, Cardiovascular and International	$410,056	—	$414,834	$112,291	$371,758	$60,487	$1,369,426
Warren Nighan	SVP & GM, Global Supply Chain, Quality and Regulatory Affairs Stock Awards: The stock awards column represents aggregate grant date fair value of restricted stock unit awards and performance share awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation - Stock Compensation. Accordingly, the grant date fair value of restricted stock units was determined by multiplying the number of restricted stock units by the closing stock price on the date of grant, while the grant date fair value of performance share awards was determined using a Monte Carlo simulation. The assumptions used in the valuation of stock-based awards are discussed in Note 13 to our Audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2025. The table below shows the grant date fair value of the performance share awards included in the stock awards column for each year, and the maximum grant date value assuming that the highest level of performance conditions was achieved: --- Name	$401,309	—	$337,186	$88,391	$303,361	$34,899	$1,165,146

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
James Clemmer	CEO	$783,000	—	$2,579,215	$820,002	$783,000	$40,754	$5,005,971
James C. Clemmer	President, CEO	$783,000	—	$2,579,215	$820,002	$783,000	$40,754	$5,005,971
Stephen Trowbridge	EVP, CFO	$441,334	—	$802,765	$255,219	$286,867	$36,069	$1,822,254
Stephen A. Trowbridge	EVP, CFO	$441,334	—	$802,765	$255,219	$286,867	$36,069	$1,822,254
Laura Piccinini	SVP & GM, Endovascular Therapies and International	$401,282	—	$396,421	$126,032	$240,769	$64,876	$1,229,380
Chad T. Campbell	SVP & GM, Global Oncology and Vascular Access	$353,176	—	$318,524	$101,270	$211,906	$27,675	$1,012,551
Warren Nighan	SVP & GM, Global Supply Chain, Quality and Regulatory Affairs Stock Awards: The stock awards column represents aggregate grant date fair value of restricted stock unit awards and performance share awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation - Stock Compensation. Accordingly, the grant date fair value of restricted stock units was determined by multiplying the number of restricted stock units by the closing stock price on the date of grant, while the grant date fair value of performance share awards was determined using a Monte Carlo simulation. The assumptions used in the valuation of stock-based awards are discussed in Note 14 to our Audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2024. The table below shows the grant date fair value of the performance share awards included in the stock awards column for each year, and the maximum grant date value assuming that the highest level of performance conditions was achieved:	$392,700	—	$280,527	$89,188	$196,350	$36,317	$995,082

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
James Clemmer	CEO	$756,154	—	$2,281,808	$718,967	$190,000	$36,762	$3,983,691
James C. Clemmer	President, CEO	$756,154	—	$2,281,808	$718,967	$190,000	$36,762	$3,983,691
Stephen Trowbridge	EVP, CFO	$425,311	—	$548,911	$172,949	$69,628	$33,080	$1,249,879
Stephen A. Trowbridge	EVP, CFO	$425,311	—	$548,911	$172,949	$69,628	$33,080	$1,249,879
Laura Piccinini	SVP & GM, Endovascular Therapies and International	$334,378	—	$303,494	$95,627	$50,401	$59,536	$843,436
David D. Helsel	SVP, Global Operations and R&D	$371,345	—	$254,471	$80,178	$46,680	$32,951	$785,625
Chad T. Campbell	SVP & GM, Global Oncology and Vascular Access	$339,749	—	$274,904	$86,623	$51,433	$25,327	$778,036

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
James C. Clemmer	President, CEO	$736,154	—	$3,156,377	$991,335	$740,000	$35,862	$5,659,728
James Clemmer	CEO	$736,154	—	$3,156,377	$991,335	$740,000	$35,862	$5,659,728
Laura Piccinini	SVP & GM, International Stock Awards: The stock awards column represents aggregate grant date fair value of restricted stock unit awards and performance share awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation - Stock Compensation. Accordingly, the grant date fair value of restricted stock units was determined by multiplying the number of restricted stock units by the closing stock price on the date of grant, while the grant date fair value of performance share awards was determined using a Monte Carlo simulation. The assumptions used in the valuation of stock-based awards are discussed in Note 14 to our Audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2023. The table below shows the grant date fair value of the performance share awards included in the stock awards column for each year, and the maximum grant date value assuming that the highest level of performance conditions was achieved:	$355,679	—	$483,872	$510,582	$177,839	$101,004	$1,628,976
Stephen Trowbridge	EVP, CFO	$409,692	—	$624,894	$196,264	$267,800	$32,077	$1,530,727
Stephen A. Trowbridge	EVP, CFO	$409,692	—	$624,894	$196,264	$267,800	$32,077	$1,530,727
Chad T. Campbell	SVP & GM, Global Oncology and Vascular Access	$324,146	—	$370,157	$116,259	$195,937	$24,110	$1,030,609
David D. Helsel	SVP, Global Operations and R&D	$360,529	—	$342,292	$107,512	$181,280	$32,044	$1,023,657

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
James Clemmer	CEO	$720,000	—	$1,598,221	$539,230	$1,152,000	$36,462	$4,045,913
James C. Clemmer	President, CEO	$720,000	—	$1,598,221	$539,230	$1,152,000	$36,462	$4,045,913
Stephen A. Trowbridge	EVP, CFO	$400,000	—	$443,943	$149,785	$384,000	$28,985	$1,406,713
Stephen Trowbridge	EVP, CFO	$400,000	—	$443,943	$149,785	$384,000	$28,985	$1,406,713
David D. Helsel	SVP, Global Operations and R&D	$352,000	—	$221,384	$74,694	$281,600	$30,688	$960,366
Warren Nighan	SVP, Quality and Regulatory Affairs	$327,000	—	$205,667	$69,387	$261,600	$33,512	$897,166
Chad T. Campbell	SVP & GM, Vascular Access and Oncology	$314,001	$2,900	$197,485	$66,631	$251,201	$21,646	$853,864

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
James Clemmer	CEO	$716,164	—	$1,245,695	$540,596	$576,000	$38,176	$3,116,631
James C. Clemmer	President, CEO	$716,164	—	$1,245,695	$540,596	$576,000	$38,176	$3,116,631
Michael Greiner	—	$270,750	—	$380,396	$164,953	—	$462,668	$1,278,767
Stephen Trowbridge	EVP, CFO	$401,448	—	$281,360	$164,727	$194,000	$34,104	$1,075,639
Stephen A. Trowbridge	EVP, CFO	$401,448	—	$281,360	$164,727	$194,000	$34,104	$1,075,639
Scott Centea	SVP and GM, Peripheral Vascular	$261,747	—	$239,009	$230,710	$84,943	$24,959	$841,368
David D. Helsel	SVP, Global Operations and R&D	$349,835	—	$172,455	$74,780	$140,800	$31,486	$769,356
Brent J. Boucher	—	$324,529	—	$160,203	$69,468	$130,800	$31,526	$716,526

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
James C. Clemmer	President, CEO	$686,575	—	$1,198,199	$365,238	$714,000	$37,478	$3,001,490
James Clemmer	CEO	$686,575	—	$1,198,199	$365,238	$714,000	$37,478	$3,001,490
Former EVP	CFO	$418,989	—	$479,286	$146,092	$279,786	$31,212	$1,355,365
David D. Helsel	SVP, Global Operations and R&D	$333,945	—	$337,236	$102,796	$156,519	$27,766	$958,262
Stephen Trowbridge	EVP, CFO	$333,888	—	$323,652	$98,655	$154,683	$30,521	$941,399
Stephen A. Trowbridge	EVP, CFO	$333,888	—	$323,652	$98,655	$154,683	$30,521	$941,399

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
James C. Clemmer	President, CEO	$643,269	—	$1,418,527	$366,586	$273,000	$41,239	$2,742,621
James Clemmer	CEO	$643,269	—	$1,418,527	$366,586	$273,000	$41,239	$2,742,621
Former EVP	CFO	$399,231	—	$397,676	$102,769	$111,930	$31,431	$1,043,037
David D. Helsel	SVP, Global Operations and R&D	$133,481	—	$410,300	$252,110	$24,846	$6,092	$826,829
Stephen A. Trowbridge	EVP, CFO	$323,342	—	$237,874	$61,476	$61,751	$34,173	$718,616
Stephen Trowbridge	EVP, CFO	$323,342	—	$237,874	$61,476	$61,751	$34,173	$718,616

Executive changes

Person	Role	Change	Effective	Filed
James C. Clemmer	President and Chief Executive Officer	Retired	2026-11-30	2026-02-03
Jan Stern Reed	chair of the Nominating, Compliance and Corporate Governance Committee	Appointed	2024-02-08	2024-02-13
Wesley Johnson	chair of the Audit Committee	Appointed	2024-02-08	2024-02-13
Dennis Meteny	chair of the Audit Committee	Resigned	2024-01-31	2024-01-22
Dennis Meteny	member of the Board of Directors	Retired	2024-01-31	2024-01-22
David D. Helsel	Senior Vice President of Global Operations and R&D	Resigned	2024-01-12	2024-01-05
Howard W. Donnelly	Class II director	Appointed	2023-11-14	2023-11-16
Jan Stern Reed	Class II director	Appointed	2023-11-14	2023-11-16
James C. Clemmer	Class II director	Appointed	2023-11-14	2023-11-16
Eileen O. Auen	Class II director	Appointed	2023-11-14	2023-11-16
Lorinda Burgess	Class III director	Appointed	2023-07-19	2023-07-24
Michael Tarnoff	Class I director	Appointed	2022-11-03	2022-11-04
Dennis Meteny	Class I director	Appointed	2022-11-03	2022-11-04

Key facts CIK 1275187 CUSIP 03475V101 13F (30d) 4 filings 4 filers Visit website Investor relations